circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.
Ling Y, Liang G, Lin Q, Fang X, Luo Q, Cen Y, Mehrpour M, Hamai A, Liu Z, Shi Y, Li J, Lin W, Jia S, Yang W, Liu Q, Song E, Li J, Gong C.
Ling Y, et al. Among authors: fang x.
Mol Cancer. 2022 Jan 3;21(1):8. doi: 10.1186/s12943-021-01476-7.
Mol Cancer. 2022.
PMID: 34980129
Free PMC article.